dr. eeson sinthamoney md (mal), mrcog (london), dffp (uk) fellowship in reproductive medicine...

41
ROLE OF PROGESTERONE IN THREATENED AND RECURRENT MISCARRIAGE Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility Specialist Pantai Hospital Kuala Lumpur

Upload: sharlene-paul

Post on 26-Dec-2015

219 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

ROLE OF PROGESTERONE IN THREATENED AND RECURRENT MISCARRIAGE

Dr. Eeson SinthamoneyMD (Mal), MRCOG (London), DFFP (UK)

Fellowship in Reproductive Medicine (UK/Singapore)

Consultant Obstetrician, Gynaecologist & Fertility Specialist

Pantai Hospital Kuala Lumpur

Page 2: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PARAMETERS

1. Recurrent miscarriages – definition, causes and role of progesterone

2. Threatened miscarriages – definition, prognosis and role of progesterone

3. Immunological basis – progesterone role

4. Summary & conclusion

Page 3: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

ULTIMATELY…………

Is there or isn’t there a role for progesterone therapy in patients with recurrent miscarriage and threatened miscarriage?

Page 4: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

MANAGING WOMEN WITH RECURRENT LOSSES: A NEVER ENDING CONTROVERSY…….

Up to 50% of them will have no identifiable reason

The need to be evidence-based in investigation and management

Evidence is a moving target! In the unexplained group, up to 75% have

a term live birth with TLC alone

Page 5: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

DEFINING RECURRENCE

Three or more consecutive pregnancy losses occurring before 24 weeks of gestation

Royal College of Obstetricians and GynaecologistsGuideline 17 – The investigation and treatment of couples with recurrent miscarriage. May 2003 ASRM 2008

definition

Page 6: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

≥ 2 OR ≥ 3 ? Based on the assumption that prevalence of

possible causes will be different in those with 2 compared to those with ≥3 miscarriages

No such difference found! However, this increases scale of the problem

from 1% to 5% of couples trying to conceive Habayeb Om, Konje JC. The one-stop recurrent miscarriage clinic: an evaluation of its

effectiveness and outcome. Human Reproduction 2004;19:2952-8

Hogge WA et al. the clinical use of karyotyping spontaneous abortions. Am J Obstet Gynaecol 2003;189:397-400

Jaslow CR et al. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2009

Page 7: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

WHAT CAUSES RECURRENT LOSSES ?

Page 8: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Cause n

Prothrombotic state 54

Chromosomal anomaly 11

Uterine anomaly 53

Polycystic ovaries 13

Retarded endometrium 54

Unexplained 188

Unknown 79

Total 452

Li TC et al. Pattern of pregnancy loss in women with recurrent miscarriages after referral, according to diagnostic criteria. Fertility and Sterility.2002;78(5):1100-1106

Causes

Page 9: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

OSAMA M.H.HABAYEB AND JUSTIN C.KONJE. THE ONE-STOP RECURRENT MISCARRIAGE CLINIC: AN EVALUATIONOF ITS EFFECTIVENESS AND OUTCOME. HUMAN REPRODUCTION VOL.19, NO.12 PP. 2952–2958, 2004

Causes

Page 10: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

EVIDENCE BASED INVESTIGATION AND TREATMENT

1. Genetic factors

2. Anatomical factors

3. Polycystic ovarian syndrome

4. Bacterial vaginosis

5. Antiphopholipid antibody syndrome

1. TORCHES2. Diabetes3. Thyroid

disorders4. Autoimmune

disorders

Progestrone Aspirin Heparin Steroids hCG✔

?

Page 11: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

ISSUES

1. Do we assess all couples for genetic causes?

2. How do we prepare PCO patients pre-conceptually?

3. In patients without APL antibodies, does empherical aspirin or heparin help?

4. What about other thrombophilias?5. How do we assess for anatomical

defects?6. Finding and treating BV

Page 12: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PROGESTERONE

a. LPD was first described by Jones in 1949

b. as a clinical entity, it has been poorly characterised

c. conflicting evidence on LPDd. exogenous progesterone

supplementation remains a common intervention for both threatened and idiopathic recurrent miscarriages

Page 13: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PROGESTERONE: CURRENT EVIDENCE No evidence to support the routine use of

progesterone in the first trimester to prevent miscarriage

However, subgroup analysis of women with RM showed a statistically significant decrease in miscarriage rate compared to placebo or no treatment

The route of treatment did not influence the resultsHaas DM et al. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008

Page 14: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

CONCLUSION Give progesterone in recurrent miss-carriers especially in idiopathic cases

However, no evidence to support routine use in first trimester to prevent miscarriage

Role in threatened miscarriage?

Page 15: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

THREATENED MISCARRIAGE A threatened miscarriage is defined

as vaginal bleeding, usually painless, that occurs in the first 24 weeks in a viable pregnancy without cervical dilatation.

It is common, especially in the first trimester, occurring in 14%–21% of all pregnancies

Important causes include chromosomal abnormalities, which occur in about 70% of the cases

Page 16: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

THREATENED MISCARRIAGE Prognosis of threatened miscarriage

with expectant management: -Gestational age: 29% of foetuses

presenting at 5–6 weeks, 8.2% at 7–12 weeks and 5.6% at 13–20 weeks, miscarried

-Severity of bleed: those who had active fresh bleeding (excluding spotting), and a viable foetus at presentation (average gestation period was 8 weeks), the miscarriage rate was 9.3%.

Basama FM, Crosfill F. The outcome of pregnancies in 182 women with threatened miscarriage. Arch Gynecol Obstet 2004; 270:86-90.Johns J, Jauniaux E. Threatened miscarriage as a predictor of obstetric outcome. Obstet Gynecol 2006; 107:845-50

Page 17: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

WHY ISN’T THERE EVIDENCE TO SUPPORT THE USE OF PROGESTERONE IN TREATMENT OF THREATENED MISCARRIAGE?

Page 18: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Conclusion: Corpus luteal support with dydrogesterone has been shown to reduce the incidence of pregnancy loss in threatened abortion during the first trimester in women without a history of recurrent abortion.

Page 19: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

THEORETICAL CONSIDERATIONS What role does progesterone play in

maintaining a successful pregnancy? Therefore, based on sound scientific

understanding is there adequate justification to give our threatened miscarriage patients progesterone?

Page 20: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Successful mammalian pregnancy depends upon tolerance of a genetically incompatible fetus by the maternal immune system.

Page 21: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

General responce

Secondary responce

Type 2/ Humoral Type 1/Cellular

granulocytes

macrophages

antibodiesT cells

Differentiate into Th1 and Th2 lymphocytes, which secrete different

types of IL and IFN

Immunology – back to basics

Page 22: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

IMMUNOLOGY OF PREGNANCY

Medawar’s ‘fetal allograft’ hypothesis 1953:

Fetal survival was d/t anatomical separation of fetus, antigenic immaturity of fetus and immunological inertness of mother (high steroids)

Medawar-shwartzman paradox

Page 23: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

IMMUNOLOGY OF PREGNANCY

Tolerance is now believed to depend in part on the interactions of cytokines secreted by maternal and fetal cells at the site of implantation.

Fetal-Maternal Interface

Page 24: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

An inflammatory response with predominant pro-inflammatory Th1 cytokines is necessary for initial implantation with invasion of trophoblasts and induction of angioneogenesis.

Fetal-Maternal Interface

Keleman K, Paldi A, Tinneberg H, Torok A, Szekeres-Bartho J: AJRI 1998; 39: 351-355

IMMUNOLOGY OF PREGNANCY

Page 25: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

But thereafter the potential detrimental effects of the

pro-inflammatory response are counteracted by anti-inflammatory cytokines (TGF-B2) involving a Th1 to Th2 shift.

Fetal-Maternal Interface

IMMUNOLOGY OF PREGNANCY

Page 26: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

ANTI VERSUS PRO-INFLAMMATORY CYTOKINES

Th-1 cytokines (TNF-, IFN-, IL-2, IL-12, Il-18) induce several cell-mediated cytotoxic and inflammatory reactions

Th-2 cytokines (IL-4, IL-5, IL-6, IL-10, IL-13) are associated with B cell antibody production

Th-2 cytokines downregulate Th-1-type reactivity.

Page 27: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Shift towards TH-2 response, resulting in:Anti-inflammatory cytokines > pro-inflammatory cytokines“IMMUNOMODULATION”

Page 28: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Progesterone ?

Page 29: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PROGESTERONE – ROLE IN IMMUNOLOGY OF PREGNANCY When antigens on trophoblast are

recognized, peripheral blood lymphocytes and CD56+ cells in decidua develop specific progesterone receptors

If sufficient progesterone present these cells produce a protein called Progesterone Induced Blocking Factor (PIBF)

PIBF is the pivotal mediator in progesterone dependent immunomodulation*DH Munn et al. Prevention of allogenic foetal rejection by tryptophan catabolism. Science 281 (1998) 1191-93

Page 30: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PIBF ANTI-ABORTIVE EFFECTS OF PROGESTERONE

Induces increased production and predominance of Th2 cytokines.

Downregulates expression of the prothrombinase fgl2.

Szekeres-Bartho J, Wegmann T: J Reprod Immunol 1996; 31: 81-95.

Page 31: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

0

1

2

3

4

5

6

7

8

9

10

Progesterone Receptors R

EC

EP

TO

R +

CELLS

%

NO

N

PR

EG

NA

NT

1st

TR

IMES

TER

AB

OR

TIO

N

2n

d T

RIM

ES

TER

PR

ETER

M D

EL.

3rd

TR

IMES

TER

Szekeres-Bartho J et al. Lymphocytic progesterone receptors in normal and pathological human pregnancy. J Reprod Immunol. 1989 Dec;16(3):239-47

Page 32: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

LOOKING FOR EVIDENCE1.Does PIBF really modulate the

immunological reaction towards a Th-2 bias in pregnancy?

Effects of PIBF on selected type 1 and type 2 cytokines secretion from peripheral blood mononuclear cells from:

30 women with unexplained RSM

18 women undergoing PTD

11 women normal pregnancy

13 healthy non pregnant womentype 2 cytokines significantly increased in pregnant groups, with Th-2 bias but did not effect non-pregnant women

Raghupathy R et al. Progesterone –induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J reprod Immunology 80 (2009) 91-99

Page 33: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

EVIDENCE:22. PIBF and cytokine levels in normal

versus threatened miss-carriers 30 women with threatened miscarriage

20 healthy pregnant women, 6-24 weeks

Serum + urine PIBF, IL10, IL6, TNF, IFN measured

1. PIBF concentration in urine and serum of threatened miss-carriers significantly lower than in healthy pregnant women

2. Threatened miss-carriers significantly lower serum levels of anti-inflammatory cytokines and higher pro-inflammatory cytokines than healthy controls

Hudic I et al. Progesterone-induced blocking factor (PIBF) and Th(1)/Th(2) cytokine in women with threatened spontaneous abortion. J Perinat Med. 2009;37(4):338-42

Page 34: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

EVIDENCE: 33. Does progesterone treatment make a

difference on hormone profile? 27 women with threatened miscarriage

treated for 10 days with dydrogesterone 16 healthy pregnant controls, no treatment Serum P4 and E2 levels and urine PIBF

measured1. Serum progesterone in controls increased as pregnancy progressed but not threatened cases

2. PIBF in threatened cases initially low, significantly increased after treatment, reaching normal healthy control levels

Kalinka J et al. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol. 2005 Apr;53(4):166-71

Page 35: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

EVIDENCE: 4 Does dydrogesterone change the type

of cytokines produced? 30 women with unexplained RSM

Peripheral blood mononuclear cells (PBMC) from venous blood stimulated with phytohaemagglutinin (PHA)

IFN-, TNF-, IL-4,IL-6,IL-10 and PIBF measuredDydrogesterone significantly inhibited the

production of the Th1 cytokines IFN-,TNF- and induced an increase in the levels of the Th2 cytokines IL-4 and IL-6 resulting in a substantial shift in the ratio of Th1/Th2 cytokinesRaghupathy R et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOGAugust 2005, Vol. 112, pp. 1096–1101

Page 36: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

PROGESTOGENS

Page 37: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

WHICH PROGESTOGEN IS BEST? Medroxyprogesterone Has androgenic and anabolic effects Early case report linking first trimester use to CAH in a male

neonate (1969) Later and larger studies showed no association FDA – category X – contraindicated if are / may become

pregnant

17-hydroxyprogesterone caproate Reports of fetal genital abnormalities and virilization

(Cochrane 2003) Recent evidence – reduces PTD risk when given from 16

weeks onwards (NEJM 2003)

Dydrogesterone No androgenic effects No reports of fetal abnormalities except one when used

together with 17OHPC (1977)

Page 38: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

-Inhibition of NK cell activity-Asymmetric, pregnancy protecting a/b-Th2 bias

Summary

Page 39: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

Immunological recognition of pregnancy

Up-regulation of progesterone receptors on NK cells in decidua / lymphocytes amongst placental cells

In presence of sufficient progesterone, activated lympocytes and decidual CD56+ cells synthesise

Progesterone induced Blocking Factor (PIBF)

Effect on humoral (B cell) and cellular (T cell) immune system and reduced NK cell activity*

substantial anti-abortive effects

*J Szekeres-Bartho et al. The role of g/d T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunolo 42(1999) 44-8

Page 40: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

SUMMARY & CONCLUSION

1. Recurrent miscarriage especially idiopathic– give progesterone

2. Important ‘immunomodulatory’ role of progesterone via PIBF in immunology of pregnancy

3. Good evidence to support concept of progesterone deficiency in threatened / recurrent miscarriage

4. Threatened miscarriage – consider progesterone despite lack of RCT evidence

5. Routine use to prevent miscarriage – NO!

Page 41: Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (UK/Singapore) Consultant Obstetrician, Gynaecologist & Fertility

THANK YOU